Showing 141 - 160 results of 47,604 for search '(((( c large decrease ) OR ( ((b large) OR (a large)) decrease ))) OR ( c also increased ))', query time: 1.49s Refine Results
  1. 141
  2. 142
  3. 143
  4. 144

    Table4_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX by Cong Xu (203537)

    Published 2022
    “…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
  5. 145

    Table3_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX by Cong Xu (203537)

    Published 2022
    “…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
  6. 146

    Table6_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX by Cong Xu (203537)

    Published 2022
    “…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
  7. 147

    Table1_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.DOCX by Cong Xu (203537)

    Published 2022
    “…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
  8. 148

    Table2_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX by Cong Xu (203537)

    Published 2022
    “…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
  9. 149

    Table5_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX by Cong Xu (203537)

    Published 2022
    “…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
  10. 150
  11. 151

    Table 1_Cholesterol metabolic reprogramming drives the onset of DLBCL and represents a promising therapeutic target.docx by Lili Zhou (265076)

    Published 2025
    “…</p>Methods<p>We retrospectively analyzed clinical data from 200 DLBCL patients and 185 healthy controls, focusing on lipid and lipoprotein levels, including triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), and apolipoprotein E (ApoE). …”
  12. 152

    Data Sheet 1_Cholesterol metabolic reprogramming drives the onset of DLBCL and represents a promising therapeutic target.docx by Lili Zhou (265076)

    Published 2025
    “…</p>Methods<p>We retrospectively analyzed clinical data from 200 DLBCL patients and 185 healthy controls, focusing on lipid and lipoprotein levels, including triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), and apolipoprotein E (ApoE). …”
  13. 153
  14. 154
  15. 155
  16. 156
  17. 157

    Illustration of decline in network accuracy associated with large window sizes, using simulated data. by Sam Tilsen (406665)

    Published 2021
    “…<p>(a, b) Simulated articulatory signals associated with simulated /p/ and /t/ onsets. …”
  18. 158
  19. 159

    Supplementary Material for: High-sensitivity Troponin I Measurement in a Large Contemporary Cohort: Implications for Clinical Care by Esau D. (20563829)

    Published 2025
    “…Laboratory data, blood pressure, and anthropomorphic measures were extracted from the electronic medical record Results: Remeasurement of hsTnI did not change risk category in 92.7% of cases. Male sex, higher HDL-C, higher Hgb A1c, decreasing eGFR, and increasing systolic blood pressure were significant predictors of increased hsTnI. …”
  20. 160